234 related articles for article (PubMed ID: 33054379)
1. Tuberculosis Treatment Facilitated by Lipid Nanocarriers: Can Inhalation Improve the Regimen?
Hädrich G; Boschero RA; Appel AS; Falkembach M; Monteiro M; da Silva PEA; Dailey LA; Dora CL
Assay Drug Dev Technol; 2020 Oct; 18(7):298-307. PubMed ID: 33054379
[No Abstract] [Full Text] [Related]
2. Advances in nanotechnology-based carrier systems for targeted delivery of bioactive drug molecules with special emphasis on immunotherapy in drug resistant tuberculosis - a critical review.
Singh J; Garg T; Rath G; Goyal AK
Drug Deliv; 2016 Jun; 23(5):1676-98. PubMed ID: 26289212
[TBL] [Abstract][Full Text] [Related]
3. Current Nanotechnological Approaches for an Effective Delivery of Bioactive Drug Molecules to Overcome Drug Resistance Tuberculosis.
Garg T; Rath G; Murthy RR; Gupta UD; Vatsala PG; Goyal AK
Curr Pharm Des; 2015; 21(22):3076-89. PubMed ID: 26027577
[TBL] [Abstract][Full Text] [Related]
4. Pulmonary drug delivery systems for tuberculosis treatment.
Pham DD; Fattal E; Tsapis N
Int J Pharm; 2015 Jan; 478(2):517-29. PubMed ID: 25499020
[TBL] [Abstract][Full Text] [Related]
5. Intrinsic Antibacterial Activity of Nanoparticles Made of β-Cyclodextrins Potentiates Their Effect as Drug Nanocarriers against Tuberculosis.
Machelart A; Salzano G; Li X; Demars A; Debrie AS; Menendez-Miranda M; Pancani E; Jouny S; Hoffmann E; Deboosere N; Belhaouane I; Rouanet C; Simar S; Talahari S; Giannini V; Villemagne B; Flipo M; Brosch R; Nesslany F; Deprez B; Muraille E; Locht C; Baulard AR; Willand N; Majlessi L; Gref R; Brodin P
ACS Nano; 2019 Apr; 13(4):3992-4007. PubMed ID: 30822386
[TBL] [Abstract][Full Text] [Related]
6. Respirable nanocarriers as a promising strategy for antitubercular drug delivery.
Mehanna MM; Mohyeldin SM; Elgindy NA
J Control Release; 2014 Aug; 187():183-97. PubMed ID: 24878180
[TBL] [Abstract][Full Text] [Related]
7. Inhaled Solid Lipid Microparticles to target alveolar macrophages for tuberculosis.
Maretti E; Rossi T; Bondi M; Croce MA; Hanuskova M; Leo E; Sacchetti F; Iannuccelli V
Int J Pharm; 2014 Feb; 462(1-2):74-82. PubMed ID: 24374224
[TBL] [Abstract][Full Text] [Related]
8. Targeting pulmonary tuberculosis using nanocarrier-based dry powder inhalation: current status and futuristic need.
Patil TS; Deshpande AS; Deshpande S; Shende P
J Drug Target; 2019 Jan; 27(1):12-27. PubMed ID: 29561179
[TBL] [Abstract][Full Text] [Related]
9. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
10. Inhalable poly(lactic-co-glycolic acid) (PLGA) microparticles encapsulating all-trans-Retinoic acid (ATRA) as a host-directed, adjunctive treatment for Mycobacterium tuberculosis infection.
O'Connor G; Krishnan N; Fagan-Murphy A; Cassidy J; O'Leary S; Robertson BD; Keane J; O'Sullivan MP; Cryan SA
Eur J Pharm Biopharm; 2019 Jan; 134():153-165. PubMed ID: 30385419
[TBL] [Abstract][Full Text] [Related]
11. Selective drug deposition in lungs through pulmonary drug delivery system for effective management of drug-resistant TB.
Sankhe K; Khan T; Bhavsar C; Momin M; Omri A
Expert Opin Drug Deliv; 2019 May; 16(5):525-538. PubMed ID: 31007100
[TBL] [Abstract][Full Text] [Related]
12. Potential and development of inhaled RNAi therapeutics for the treatment of pulmonary tuberculosis.
Man DK; Chow MY; Casettari L; Gonzalez-Juarrero M; Lam JK
Adv Drug Deliv Rev; 2016 Jul; 102():21-32. PubMed ID: 27108702
[TBL] [Abstract][Full Text] [Related]
13. Microparticles of rifampicin: comparison of pulmonary route with oral route for drug uptake by alveolar macrophages, phagocytosis activity and toxicity study in albino rats.
Parikh R; Patel L; Dalwadi S
Drug Deliv; 2014 Sep; 21(6):406-11. PubMed ID: 24215141
[TBL] [Abstract][Full Text] [Related]
14. Nanocarriers for respiratory diseases treatment: recent advances and current challenges.
Trapani A; Gioia SD; Castellani S; Carbone A; Cavallaro G; Trapani G; Conese M
Curr Top Med Chem; 2014; 14(9):1133-47. PubMed ID: 24678708
[TBL] [Abstract][Full Text] [Related]
15. Inhaled Pyrazinoic Acid Esters for the Treatment of Tuberculosis.
Young EF; Perkowski E; Malik S; Hayden JD; Durham PG; Zhong L; Welch JT; Braunstein MS; Hickey AJ
Pharm Res; 2016 Oct; 33(10):2495-505. PubMed ID: 27351427
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxicity screening of emulsifiers for pulmonary application of lipid nanoparticles.
Steiner V; Öhlinger K; Corzo C; Salar-Behzadi S; Fröhlich E
Eur J Pharm Sci; 2019 Aug; 136():104968. PubMed ID: 31233864
[TBL] [Abstract][Full Text] [Related]
17. Development of Lipid Nanocarriers for Tuberculosis Treatment: Evaluation of Suitable Excipients and Nanocarriers.
Hädrich G; Vaz GR; Boschero R; Appel AS; Ramos C; Halicki PCB; Bidone J; Teixeira HF; Muccillo-Baisch AL; Dal-Bó A; Silva Pinto L; Dailey LA; Da Silva PEA; Ramos DF; Dora CL
Curr Drug Deliv; 2021; 18(6):770-778. PubMed ID: 33583376
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of the effectiveness of lipid nanoparticle formulations loaded with anti-tubercular drugs combinations toward overcoming drug bioavailability in tuberculosis.
Banerjee S; Roy S; Bhaumik KN; Pillai J
J Drug Target; 2020 Jan; 28(1):55-69. PubMed ID: 31035816
[TBL] [Abstract][Full Text] [Related]
19. Multi-drug resistant Mycobacterium tuberculosis & oxidative stress complexity: Emerging need for novel drug delivery approaches.
Dua K; Rapalli VK; Shukla SD; Singhvi G; Shastri MD; Chellappan DK; Satija S; Mehta M; Gulati M; Pinto TJA; Gupta G; Hansbro PM
Biomed Pharmacother; 2018 Nov; 107():1218-1229. PubMed ID: 30257336
[TBL] [Abstract][Full Text] [Related]
20. Induction of
Shang S; Kats D; Cao L; Morgun E; Velluto D; He Y; Xu Q; Wang CR; Scott EA
Front Immunol; 2018; 9():2709. PubMed ID: 30538700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
